[Endogenous candida endophthalmitis in a drug dependent patient: intravenous therapy with liposome encapsulated amphotericin B].
We report this exemplary case of a drug addict with candida endophthalmitis where we used the new form of amphotericin B, encapsulated in liposomes. We were able to reconfirm the reduced number of side effects and the minimized nephrotoxicity reported by authors of other specialties. In our patient, a reduction or elimination of the yeast was probably achieved, nevertheless, he developed a traction retinal detachment. In future cases of fungal endophthalmitis, we recommend liposomal amphotericin B in higher doses.
Neppert
B
B
Universitäts-Augenklinik Hamburg.
Guthoff
R
R
Heidemann
H T
HT
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002177:Candidiasis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D009877:Endophthalmitis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D005451:Fluorescein Angiography; D006801:Humans; D007262:Infusions, Intravenous; D008081:Liposomes; D008297:Male; D009293:Opioid-Related Disorders / Q000150:complications*; D012160:Retina / Q000378:metabolism; D015819:Substance Abuse, Intravenous / Q000150:complications*; D014822:Vitreous Body / Q000378:metabolism
D004337:Drug Carriers; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B
Endogene Candida-Endophthalmitis bei einem Drogenabhängigen: intravenöse Therapie mit liposomal verkapseltem Amphotericin B.